Lv12
50 积分 2023-10-20 加入
Affinity-maturation engineering via phage display to optimize anti-idiotype antibodies for neutralizing antibody assays
21小时前
已完结
Harmonizing immunogenicity for AAV and LNP/mRNA modalities: best-practice panels for binding, neutralizing, and cellular assays with pre-existing immunity controls
21小时前
已完结
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
22小时前
已完结
Mitigation of pre-existing immunogenicity in ADA method development
22小时前
已完结
Harmonizing immunogenicity for AAV and LNP/mRNA modalities: best-practice panels for binding, neutralizing, and cellular assays with pre-existing immunity controls
1个月前
已关闭
Mitigation of pre-existing immunogenicity in ADA method development
2个月前
已关闭
Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
2个月前
已关闭
Development of a novel anti-PEG antibody assay enabling investigation of potential immunogenicity triggered by the PEG moiety of biotherapeutics
2个月前
已完结
Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
2个月前
已关闭
Mitigation of pre-existing immunogenicity in ADA method development
2个月前
已关闭
皖公网安备34019202002308
